Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Early Serum Free Light Chain Response after High-Dose Melphalan and Stem Cell Transplantation Predicts Hematologic Response in AL Amyloidosis

Vanessa Fiorini Furtado, MD, Dina Brauneis, ANP, Shayna Sarosiek, MD, Karen Quillen, MDMPH, Vaishali Sanchorawala, MD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-138500

Published: 2020

Journal Articles

Modified High Dose Versus High Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis

Camille V Edwards, MD, Dina Brauneis, ANP, Karen Quillen, MDMPH, Vaishali Sanchorawala, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141560

Published: 2020

Journal Articles

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

Vaishali Sanchorawala, Shayna Sarosiek, Amanda Schulman, Meredith Mistark, Mary Ellen Migre, Ramon Cruz, J. Mark Sloan, Dina Brauneis, Anthony C. Shelton

Blood (2020) 135 (18): 1541–1547.

https://doi.org/10.1182/blood.2019004436

Published: 2020

Journal Articles

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Shayna Sarosiek, John Mark Sloan, MD, Karen Quillen, MDMPH, Dina Brauneis, ANP, Ramon Cruz, Amanda Schulman, Salli Fennessey, Anthony Shelton, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 4578.

https://doi.org/10.1182/blood-2019-129095

Published: 2019

Journal Articles

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Ramon Cruz, Salli Fennessey, Anthony C Shelton, RN

Blood (2018) 132 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2018-99-112991

Published: 2018

Journal Articles

Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-up Analysis

Vishal K Gupta, MD, Dina Brauneis, NP, Anthony C Shelton, RN, Karen Quillen, MD MPH, John Mark Sloan, MD, Vaishali Sanchorawala, MD

Blood (2018) 132 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2018-99-111551

Published: 2018

Journal Articles

Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients

Vishal K Gupta, MD, Paul White, MD, Vaishali Sanchorawala, MD, Karen Quillen, MD MPH, Shayna Sarosiek, MD, Dina Brauneis, NP, John Mark Sloan, MD

Blood (2018) 132 (Supplement 1): 5738.

https://doi.org/10.1182/blood-2018-99-110230

Published: 2018

Journal Articles

Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation

Shayna Sarosiek, Karen Quillen, J. Mark Sloan, Dina Brauneis, Vaishali Sanchorawala

Blood (2018) 132 (7): 755–757.

https://doi.org/10.1182/blood-2018-03-838672

Published: 2018

Journal Articles

Brachial Plexopathy Following High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation for AL Amyloidosis

Vina Nguyen, MD, Dina Brauneis, NP, John Mark Sloan, MD, Shayna Sarosiek, MD, Karen Quillen, MD, Anthony C Shelton, RN, Vaishali Sanchorawala, MD

Blood (2017) 130 (Supplement 1): 5509.

https://doi.org/10.1182/blood.V130.Suppl_1.5509.5509

Published: 2017

Journal Articles

Recognizing the Existence of Heparin Induced Thrombocytopenia and Thrombosis in the Setting of High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Case Series

Shayna Sarosiek, MD, Karen Quillen, MDMPH, John Mark Sloan, MD, Dina Brauneis, NP, Vaishali Sanchorawala, MD

Blood (2017) 130 (Supplement 1): 3643.

https://doi.org/10.1182/blood.V130.Suppl_1.3643.3643

Published: 2017

Journal Articles

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Salli Fennessey, Anthony C Shelton, RN

Blood (2017) 130 (Supplement 1): 507.

https://doi.org/10.1182/blood.V130.Suppl_1.507.507

Published: 2017

Journal Articles

A Retrospective Review of Engraftment Data for Tbo-Filgrastim Vs. Filgrastim in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation

Taylor Teschner, Stephen Lo, Dina Brauneis, Anthony C Shelton, Bhavesh Shah, John Mark Sloan, Cindy Varga, Karen Quillen, Vaishali Sanchorawala

Blood (2015) 126 (23): 5484.

https://doi.org/10.1182/blood.V126.23.5484.5484

Published: 2015

Journal Articles

The Incidence of Atrial Fibrillation Among Patients with AL Amyloidosis Undergoing High Dose Melphalan and Stem Cell Transplantation (HDM/SCT): Experience at a Single Institution

Dina Brauneis, Monica Arun, Frederick L Ruberg, Anthony C Shelton, John Mark Sloan, Karen Quillen, Vaishali Sanchorawala, Cindy Varga

Blood (2015) 126 (23): 5490.

https://doi.org/10.1182/blood.V126.23.5490.5490

Published: 2015

Journal Articles

Effect of Severe Hypoalbuminemia on Myelosuppression and Other Toxicities of High Dose Melphalan and Autologous Stem Cell Transplantation in AL Amyloidosis Patients

Shin Yin Lee, Robert Meehan, John Mark Sloan, Karen Quillen, Dina Brauneis, Anthony C Shelton, Vaishali Sanchorawala

Blood (2015) 126 (23): 5499.

https://doi.org/10.1182/blood.V126.23.5499.5499

Published: 2015

Journal Articles

Effect of Severe Hypoalbuminemia on Myelosuppression and Other Toxicities of High Dose Melphalan and Autologous Stem Cell Transplantation in AL Amyloidosis Patients

Robert Meehan, MD, David Seldin, MD, John Mark Sloan, MD, Karen Quillen, MD MPH, Dina Brauneis, ANP, Anthony C Shelton, RN, Vaishali Sanchorawala, MD

Blood (2014) 124 (21): 5906.

https://doi.org/10.1182/blood.V124.21.5906.5906

Published: 2014

Journal Articles

Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center

Vaishali Sanchorawala, MD, Gheorghe Doros, Karen Quillen, MD, MPH, John Mark Sloan, MD, Anthony C Shelton, RN, Dina Brauneis, ANP, Kathleen T Finn, ANP, David C Seldin, MD, PhD

Blood (2013) 122 (21): 3328.

https://doi.org/10.1182/blood.V122.21.3328.3328

Published: 2013

Journal Articles

Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation

Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Dina Brauneis, ANP, Karen Quillen, MD, MPH, Nancy T Andrea, MD, John Mark Sloan, MD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 2019.

https://doi.org/10.1182/blood.V120.21.2019.2019

Published: 2012

NARROW

Early Serum Free Light Chain Response after High-Dose Melphalan and Stem Cell Transplantation Predicts Hematologic Response in AL Amyloidosis

Modified High Dose Versus High Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-up Analysis

Safety of Autologous Stem Cell Transplantation in Patients with Known HTLV-1 Infection: A Case Series of 4 Patients

Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation

Brachial Plexopathy Following High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation for AL Amyloidosis

Recognizing the Existence of Heparin Induced Thrombocytopenia and Thrombosis in the Setting of High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Institution Case Series

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

A Retrospective Review of Engraftment Data for Tbo-Filgrastim Vs. Filgrastim in Patients Undergoing High Dose Chemotherapy and Autologous Stem Cell Transplantation

The Incidence of Atrial Fibrillation Among Patients with AL Amyloidosis Undergoing High Dose Melphalan and Stem Cell Transplantation (HDM/SCT): Experience at a Single Institution

Effect of Severe Hypoalbuminemia on Myelosuppression and Other Toxicities of High Dose Melphalan and Autologous Stem Cell Transplantation in AL Amyloidosis Patients

Effect of Severe Hypoalbuminemia on Myelosuppression and Other Toxicities of High Dose Melphalan and Autologous Stem Cell Transplantation in AL Amyloidosis Patients

Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center

Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only